How Long Will You Stay — on Abiraterone?

A single higher PSA reading does not usually change anything on its own. PSA can fluctuate for reasons unrelated to disease progression — including a urinary tract infection or natural variation between laboratory measurements. Your team will repeat the test and compare the direction across several readings before drawing any conclusion. One number is data. A consistent upward direction across repeated readings is a signal worth acting on. Ask your doctor which pattern they are seeing in your results.

An unplanned break is not recommended without first discussing it with your oncologist. Abiraterone works by continuously blocking hormone production, and stopping it gives the cancer an uncontrolled hormone environment that can allow rapid change in disease activity. If a side effect is making it difficult to continue, your team may be able to adjust the dose, add a supporting medicine, or address the specific symptom directly. A planned, supervised pause is a different clinical decision from stopping because you feel unwell — tell your team what you are experiencing rather than managing it alone.

Feeling well is a positive sign, and it generally means the treatment is being tolerated. But feeling well does not tell you or your team whether the cancer is still responding — that is what the PSA tests and scans are for. The monitoring schedule continues regardless of how you feel, because disease can progress before it is felt, and catching that early keeps more options open. If your markers remain stable and you are tolerating the tablet, you continue. The monitoring is what confirms that for you at each visit.

Often you will not feel it before the blood tests and scans show a change. Some people notice new bone pain or fatigue before a formal review, and those symptoms should always be reported without waiting for the next scheduled appointment. But many people whose PSA begins to rise or whose scans show small changes feel no different at first. This is one of the main reasons the monitoring visits exist and are not optional. Missing them removes your team's clearest early signal.

Duration is a consequence of the drug working, not a cause. A longer time on abiraterone means the cancer has remained stable — which is the goal — but it does not make the treatment more effective going forward. The cancer's biology, not the calendar, decides how long the response lasts. What you can influence is how consistently you take the tablet as prescribed, and how promptly you report any new symptoms between appointments.

Abiraterone is almost always taken alongside a low dose of prednisone or prednisolone. That steroid is not cosmetic — it compensates for a hormonal change that abiraterone causes in the adrenal glands. When abiraterone is stopped, the prednisone is typically tapered and withdrawn in a supervised way, not discontinued at the same time without guidance. Do not stop the prednisone on your own when abiraterone ends. Your oncologist will give you specific instructions on when and how to come off it.